Medical Health Cluster


For Hospitalized Patients with COVID-19 Pneumonia, Tofacitinib May Be Beneficial

Compared with placebo, this Janus kinase inhibitor was associated with lower risk for death or respiratory failure in such patients. In patients hospitalized with COVID-19, excess inflammation generally underlies clinical progression. By reducing cytokine production, Janus kinase (Jak) inhibitors tamp down inflammation. Now, investigators report results of an industry-supported trial […]

Read More